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Abstract: Giant cell arteritis (GCA) is a relapsing disease.
However, the nature, chronology, therapeutic impact, and clinical
consequences of relapses have been scarcely addressed. We condu-
cted the present study to investigate the prevalence, timing, and
characteristics of relapses in patients with GCA and to analyze
whether a relapsing course is associated with disease-related
complications, increased glucocorticoid (GC) doses, and GC-related
adverse effects. The study cohort included 106 patients, longitu-
dinally followed by the authors for 7.83.3 years. Relapses were
defined as reappearance of disease-related symptoms requiring
treatment adjustment. Relapses were classified into 4 categories:
polymyalgia rheumatica (PMR), cranial symptoms (including ische-
mic complications), systemic disease, or symptomatic large vessel
involvement. Cumulated GC dose during the first year of treatment,
time required to achieve a maintenance prednisone dose <10mg/d
(T10), <5mg/d (T5), or complete prednisone discontinuation (T0),
and GC-related side effects were recorded. Sixty-eight patients
(64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or
more. First relapse consisted of PMR in 51%, cranial symptoms in
31%, and systemic complaints in 18%. Relapses appeared predomi-
nantly, but not exclusively, within the first 2 years of treatment, and
only 1 patient developed visual loss. T10, T5, and T0 were
significantly longer in patients with relapses than in patients without
relapse (median, 40 vs 27 wk, p <0.0001; 163 vs 89.5 wk,
p ¼ 0.004; and 340 vs 190 wk, p¼0.001, respectively). Cumulated
prednisone dose during the first year was significantly higher in
relapsing patients (6.21.7g vs 5.40.78g, p¼0.015). Osteoporosis
was more common in patients with relapses compared to those
without (65% vs 32%, p¼0.001). In conclusion, the results of the
present study provide evidence that a relapsing course is associated
with higher and prolonged GC requirements and a higher frequency
of osteoporosis in GCA.
(Medicine 2014;93: 194–201)
Abbreviations: CRP = C-reactive protein, ESR = erythrocyte
sedimentation rate, GC = glucocorticoids, GCA = giant cell
arteritis, Hb = hemoglobin, IQR = interquartile range, PDN =
prednisone, PMR = polymyalgia rheumatica, SD = standard
deviation, SIR = systemic inflammatory response, TNF = tumor
necrosis factor.
INTRODUCTION
Giant cell arteritis (GCA) is a granulomatous arteritispredominantly affecting large and medium-sized ves-
sels.18,27 Treatment with high-dose glucocorticoids (GC)
results in prompt and remarkable improvement of symptoms
and reduces the risk of ischemic complications.2 However,
reduced GC doses do not completely abolish essential
pathways involved in disease persistence, and consequently,
the course of GCA may be troubled by relapses.5,8,27
Recrudescence of GCA activity is common, occurring in at
least 43% of patients in population-based studies3,26 and up
to 80% in clinical trials with adjuvant therapies.15,16,19,20,22
The remarkable variability in the reported prevalence of
relapses may be related to heterogeneity in the definition
of relapses and to variability in the GC-tapering schedules.
Definition of relapse, flare, or recurrence considerably varies
across different studies.16,21–23,26 While in some publications
definition of relapse has been based on clinical
grounds,15,16,19 in others, isolated increases in acute-phase
reactants have been considered disease flares.24
In addition, although this has not been formally
evaluated, initial doses and tapering schedules seem to
influence relapse rate in GCA.17,20 In this regard, it is
noteworthy that the higher relapse rates have been observed
in the context of clinical trials with adjuvant therapies where
GC tapering is more aggressive than in standard of care
settings, and when alternate-day GC tapering is
applied.15,16,19,20,22 Consistently, a detailed review of
treatments received by patients with isolated polymyalgia
rheumatica (PMR) suggests that starting with lower GC
doses is associated with higher relapse rates.13
Relapse rate is a commonly used primary endpoint in
clinical trials with patients with GCA. However, although
frequency of relapses has been reported in various stu-
dies,15,16,19,20,22,26 limited information exists regarding the
From the Vasculitis Research Unit (MAA, AG-M, SP-G, IT-B, MC-B,
EP-R, GE-F, MB, JH-R, MCC), Department of Autoimmune Diseases,
Hospital Clınic, University of Barcelona, Institut d’Investigacions Bio-
me`diques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
Correspondence: Maria C. Cid, MD, Vasculitis Research Unit, Depart-
ment of Systemic Autoimmune Diseases, Hospital Clınic, Villarroel
170, 08036 Barcelona, Spain (e-mail: mccid@clinic.ub.es).
Results partially presented at the Annual Scientific Meeting of the
American College of Rheumatology 2012, Washington, DC (Novem-
ber 10–14, 2012).
Conflicts of Interest and Funding Sources: The authors declare no
conflicts of interest. Supported by Ministerio de Economıa y
Competitividad (SAF 08/04328 y SAF 11/30073). MA Alba was
supported by Consejo Nacional de Ciencia y Tecnologıa (CONA-
CyT), Mexico and by the Agencia de Gestio d’Ajuts Universitaris i
de Recerca (AGAUR) (Generalitat de Catalunya). G Espıgol-Frigole
was supported by Instituto de Salud Carlos III. M Butjosa and
S Prieto-Gonzalez were supported by Premi Fi de Reside`ncia
(Hospital Clınic).
Copyright © 2014 by Lippincott Williams & Wilkins.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000000033
194 | www.md-journal.com Medicine • Volume 93, Number 5, July 2014
clinical characteristics and predictors of relapses, and accom-
panying blood test abnormalities, which have been only
specifically addressed in a previous study.23 Moreover, it has
not been clearly demonstrated whether a relapsing course
results in increased disease or treatment-related morbidity in
these patients. Therefore, we conducted the present study to
investigate the prevalence, timing, predictors, and main
features of relapses in a longitudinally followed cohort of
patients with GCA with long-term follow-up. In addition, we
analyzed whether a relapsing course was associated with
disease-related ischemic complications, higher cumulated GC
doses, more prolonged treatment periods, and/or higher
frequency of GC-related adverse effects.
PATIENTS AND METHODS
Between 1995 and 2007, 187 individuals were diag-
nosed with biopsy-proven GCA at our institution (Hospital
Clınic, Barcelona, Spain). Among them, patients treated by
the authors who underwent a regular follow-up for at least 4
years were selected. From the initial 187 patients diagnosed,
81 were excluded for the following reasons: 31 were
subsequently treated at other departments or institutions, 19
died early during follow-up, 14 were transferred to nursing
homes for advanced dementia, and 17 moved to other
regions or had deficient compliance with the scheduled
follow-up visits.
The remaining 106 patients were uniformly evaluated,
treated, and longitudinally followed by the authors for an
average of 7.83.3 years (range, 4–15 yr). Clinical and
laboratory findings at disease diagnosis were recorded. A
combination of clinical and blood test abnormalities was used to
evaluate the intensity of the systemic inflammatory response
(SIR) as previously reported.6,7,14 These included fever >38 °C,
weight loss ³4kg, hemoglobin (Hb) <11g/L, and erythrocyte
sedimentation rate (ESR) ³85mm/h. Patients with 3 or 4 of
these items were considered to have a strong SIR, whereas
patients with 2 were considered to have a weak SIR. Patients
underwent clinical assessments in our outpatient facility every 3
months for the first 2 years after diagnosis and approximately
every 4–6 months thereafter. ESR, C-reactive protein (CRP),
blood cell counts, and Hb concentration were determined at each
visit. The treatment protocol consisted of an initial prednisone
(PDN) dose of 1 mg/kg per day (up to 60mg/d) for 1 month.
Intravenous methylprednisolone pulse therapy (1g daily for 3d)
was initially administered to patients with recent (<48h) visual
loss. PDN was subsequently tapered at 10mg/wk. When reach-
ing 20mg/d, this dose was maintained for 1–2 weeks and then
reduced to 15mg/d, which was maintained for 1 month. A
further reduction to a maintenance dose of 10mg/d was
attempted. If tolerated, a reduction to 7.5mg/d was tried after 3–
6 months. Subsequent tapering was more variable. In general, a
reduction to 5mg/d was attempted approximately 3–6 months
later and maintained for 1 year, after which a reduction of
1.25 mg/d was attempted every 6 months. Methotrexate at
15 mg/wk was added when patients experienced ³2 relapses or
had developed GC side effects. Reduction in PDN dose was
performed 1 month before the scheduled follow-up visit to
evaluate tolerance to the adjustment and to avoid severe
relapses. If disease-related symptoms (cranial manifestations or
PMR), fever, weight loss, or anemia not attributable to other
reasons after the necessary work-up occurred, PDN dose was
increased by 10–15mg/d above the previous effective dose. If
asymptomatic increases in acute-phase reactants were detected,
PDN dose was held until the next visit. When a relapse could be
defined, patients were managed as discussed above. If not, a
reduction was attempted regardless of the ESR or CRP levels.
We used a consensus definition of relapse established in
the context of international multicenter clinical trials.15,16,19
Relapse or recurrence were indistinctly defined as reap-
pearance of disease-related symptoms, usually accompanied by
elevation of acute-phase reactants that required treatment
adjustment. Relapses were categorized according to the clinical
manifestation into 4 categories: 1) PMR, 2) cranial symptoms
(headache, scalp tenderness, jaw claudication, cranial ischemic
complications), 3) systemic disease (anemia, fever, and/or
weight loss), or 4) symptomatic large vessel involvement
(extremity claudication). Cranial ischemic manifestations
included stroke, transient ischemic attacks, amaurosis fugax,
GCA-related visual loss, or diplopia. Number of relapses, time
(in weeks) from the initiation of treatment to first relapse, time
required to reach a PDN maintenance dose <10mg/d (T10),
<5mg/d (T5), and time required to complete GC withdrawal
(T0), not followed by a relapse for at least 3 months, were
recorded. Cumulated PDN doses received after the first year of
treatment were calculated. For each episode of relapsing
activity, the ESR, serum CRP, and Hb concentrations were
determined, as well as the PDN dose received at that time. In
addition, GC-related adverse effects including new or worsen-
ing hypertension, diabetes mellitus, hypercholesterolemia,
osteoporosis, cataracts, and Cushing appearance were recorded.
Measurement of bone mineral density with dual energy X-ray
absorptiometry was performed at disease diagnosis and there-
after approximately every 2 years. Osteoporosis was diagnosed
using the World Health Organization criteria–that is, bone
mineral density T-score of 2.5 standard deviations (SDs) or
more below the young adult mean.4 For screening of diabetes
and hyperlipidemia, patients had blood tests prior to each visit,
and blood pressure was periodically assessed both at their
scheduled visits and by their primary care physicians. We
recorded events as adverse events when they appeared
or worsened after GC treatment and required new treatment or
intensification of previous therapy. The study was approved by
the Ethics Committee of Hospital Clınic (Barcelona, Spain).
Statistical Analysis
Continuous variables are presented as meanSD and/or
median and interquartile range (IQR) and categorical data as
percentages. Association between relapses and selected cova-
riates was analyzed using the T-test (paired and unpaired) for
quantitative variables and the chi-square test for categorical
data. Time required to achieve maintenance PDN dose
<10 mg/d, <5mg/d, and time to treatment discontinuation
were compared between patients with and without relapses by
the Kaplan-Meier survival analysis method. Statistical signifi-
cance was defined as p<0.05. Calculations were performed
with the statistical package PAWS statistics v 18 (SPSS Inc,
Chicago, IL) and GraphPad Prism v 5.04 for Windows
(GraphPad Software, La Jolla, CA).
RESULTS
We analyzed 106 patients. Mean age at diagnosis was
757 years (range, 58–89 yr) with a male to female ratio of
1:2.6. Demographic data and main clinical features at disease
onset are depicted in Table 1.
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Chronology and Characteristics of Relapses
Sixty-eight patients (64%) relapsed during follow-up
(mean, 7.83.3 yr; range, 4–15 yr) (Figure 1). Mean time to
first relapse was 7975 weeks (range, 11–339 wk) with a
median of 51 (IQR, 89) weeks. Thirty-four of the 68 patients
(50%) relapsed during the first year after diagnosis
(Figure 2A).
PMR was the most frequent clinical manifestation
observed during the first flare (Figure 2B). Of note, severe
ischemic complications were not developed by any patient as
part of the first relapsing episode. Most patients relapsed
with the same features originally present at GCA diagnosis
(n¼52, 78%). For those who developed a different clinical
manifestation, PMR was the most frequent new feature
(n¼ 9, 75%). No patients in this series relapsed with
symptomatic large vessel involvement.
Figure 2A shows the meanSD and median (IQR) of
PDN used by patients at the time of relapse during the first 5
years of follow-up. Mean PDN dose received by the 68
patients at the first relapse was of 5.36.5mg/d with a
median of 2.5 (IQR, 7.5) mg/d. Fifty-two percent were
receiving doses 2.5mg/d (Figure 2C). PDN doses at the
time of relapse tended to decrease over time (Figure 2A).
Patients who relapsed during the first year received
8.38.2mg/d, median 7.5mg (IQR, 15), whereas patients
who relapsed during the second year were receiving
3.72.3mg, median 5mg (IQR, 2.5).
Mean ESR, CRP, and Hb levels at the time of the first
relapse were 6129mm/h, 4.03.8mg/dL, and 121.4g/L,
respectively. The inflammatory response at that time was
comparatively lower than that observed at GCA onset (ESR
8833 vs 6129mm/h, p<0.0001; CRP 1119 vs
4.0  3.8 mg/dL, p¼0.001; and Hb 11.31.6 vs 121.4g/L,
p< 0.0001). We observed an increase of 3314mm/hr in
ESR level, an increase of 2.9  2.2mg/dL in CRP concentra-
tion, and a decrease of 0.70.1g/L for Hb values between the
previous laboratory tests while in remission and the ones
performed at disease relapse.
There were significant differences in the PDN doses
used to treat relapses according to the type of recurrence
(Table 2). The lowest doses were used to treat PMR
symptoms (14.5  6.8mg/d) whereas higher doses were
employed to treat cranial manifestations (23.712.9mg/d).
ESR levels and Hb concentrations were significantly more
deviated from normal values in patients who relapsed with
systemic manifestations (see Table 2).
Thirty-eight patients (36%) had 2 or more relapses.
Distribution of relapse types was similar to that observed at
the first episode (Figure 2D). One patient developed a severe
ischemic complication (anterior ischemic optic neuritis) as
part of her second recurrence. This patient was treated for
3.5 years and regularly followed for 5 years. She subsequ-
ently abandoned regular visits and presented with a relapse
including malaise, ischemic optic neuritis, and elevation of
ESR, 4 years later. The mean PDN dose at the second flare
was 4.3  2.7 mg/d with a median of 5 (IQR 2.5) mg. ESR
(mm/h), CRP (mg/dL), and Hb (g/L) levels were 5530,
3.96.1, and 12.11.4 respectively.
Predictors of Relapse
To search for predictors of relapses, we compared initial
clinical and laboratory findings between patients with or
without recurrent disease. At disease onset, PMR and scalp
tenderness were more frequently observed in relapsing
patients (Table 3). Acute-phase reactants tended to be higher
in patients with recurrences, but only haptoglobin reached
statistical significance (3.81.6g/L vs 3.01.3g/L,
p¼ 0.042). When the intensity of the SIR was evaluated
combining clinical and laboratory findings, patients with
multiple relapses were significantly more frequent among
those with a strong SIR: 23 of 27 (85%) patients with a
strong SIR relapsed 2 or more times compared with 15 of 41
(37%) of those with a weak SIR. No other predictors of
recurrences could be identified.
Glucocorticoid Requirements and Side Effects
According to Disease Recurrences
Treatment requirements were different in both groups
of patients (Table 4). Patients with relapses required
TABLE 1. Baseline Characteristics at Diagnosis (n¼106)
General Characteristics:
Age, meanSD (range), years 75 7 (58–89)
Sex, No. Male/female (%) 29/77 (27/73)
Duration of Symptoms, MeanSD, Weeks 16 21
Cranial Symptoms at Diagnosis, N (%)
Headache 83 (78)
Jaw Claudication 47 (44)
Scalp Tenderness 49 (46)
Facial Pain+ 50 (47)
Cranial Ischemic Complications† 26 (24.5)
Polymyalgia Rheumatica 54 (51)
Systemic Manifestations, N (%)
Fever 40 (38)
Anorexia 12 (11)
Weight Loss 54 (51)
Laboratory Parameters
ESR, mm/hour 90 30.2
CRP, mg/dL 11.2 17.6
Haptoglobin, g/L 3.6 1.5
Hemoglobin, g/dL 11.3 1.4
+Includes ocular pain, tongue pain, toothache, earache, odynopha-
gia and carotidynia.
† Includes stroke, transitory ischemic attacks, amaurosis fugax,
blindness and diplopia.
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FIGURE 1. Kaplan-Meier plot of the entire series showing the
probability of relapse over time.
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significantly longer periods of time to reach a maintenance
dose of PDN <10mg/d, <5mg/d, and to completely discon-
tinue GC therapy (Figure 3). Cumulated PDN dose during
the first year was significantly higher in relapsing patients
(6.21.7g vs 5.40.78g, p¼0.015). Relapsing patients had
an increased prevalence of osteoporosis (65% for relapsing
patients vs 32% for nonrelapsing, p¼0.001). Other adverse
effects also tended to be more frequent in patients with
relapses, but differences did not reach statistical significance.
As expected, methotrexate was administered more frequently
in patients with relapses than in patients in sustained
remission (22% vs 3%, p¼ 0.009).
DISCUSSION
Limited information about the characteristics of recurrences
occurring in patients with GCA is available.23 Here, we present
detailed data about clinical and laboratory characteristics of
relapses from a cohort of uniformly treated patients with GCA
with long-term follow-up. The definition of relapse used in the
present study was similar to that used in randomized, controlled
clinical trials evaluating adjunctive therapies for GCA.15,16,19
In spite of the satisfactory initial response to GC
treatment, 64% of patients relapsed in the present series.
This percentage is somewhat higher than that reported in
population-based studies,3,26 possibly due to the more
extended follow-up of our patient cohort, but some selection
bias cannot be excluded. Although most relapses occurred
within the first 2 years of treatment, recurrences also
developed subsequently. PMR was the most frequent symp-
tom (51%) at the time of relapse, followed by cranial
manifestations (31%). In previous studies16,22,23 headache
was the leading feature (44%-60%), followed by PMR
(19%-30%),16,23 and constitutional syndrome (28%).23 There-
fore, the distribution found in the current cohort is close to
that found in other studies. It is noteworthy that disease-related
≥ 5th (8%)
0.6±1.25,
0(1.87)
1st (50%)
8.3±8.2,
7.5(15)
2nd (22%)
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3rd (10%)
2.1±2.3,
1.25(5)
4th (10%)
1.25±0.79,
1.25(0.63)
(a)
Systemic
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FIGURE 2. Characteristics and timing of flares in relapsing patients (n¼68). A) Percentage of patients relapsing per year of follow-up
and meanSD and median (IQR) prednisone dose (mg/d) received at the time of relapse. B) Percentage of relapsing patients with a
given clinical type of relapse. C) Percentage of patients receiving the indicated dose of prednisone (mg/d) at the time of the first
TABLE 2. Laboratory Characteristics and PDN Dose at Each Relapse Type
Polymyalgia Rheumatica Cranial Manifestations Systemic Disease p
ESR (mm/h) 55 28 59 28 80 26 0.038
CRP (mg/L) 3.9 3.5 4.5 4.2 3.6 4.1 ns
Hemoglobin (g/L) 12.2 1.3 12.3 1.4 11.7 1.2 0.017
Dose of prednisone (mg/d) used to treat relapse 14.5 6.8 23.7 12.9 17.9 5.6 0.002
Increment in prednisone dose (mg/d) 10 6.5 17 12 14 11 0.009
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ischemic complications seem to be extremely infrequent in the
context of controlled relapses. In previous studies the occur-
rence of ischemic manifestations has been also found to be
infrequent during follow-up (0%-6%).1,16,23 Only 1 patient in
the current series suffered anterior ischemic optic neuropathy
in the context of a delayed relapse, but this patient had
interrupted regular control visits at the time of disease
recurrence. No patient in our series relapsed with symptomatic
involvement of large vessels.
Relapses were usually accompanied by elevated levels of
ESR and CRP that were, nevertheless, lower than those observed
at disease onset. In accordance, PDN doses much lower than the
starting doses were usually effective for treating controlled
relapses. However, it must be stressed that the reported features
were obtained from patients who were closely followed with re-
assessments performed approximately every 3 months during
the first 2 years after diagnosis. We cannot exclude that severe
relapses requiring higher GC doses may occur in patients
controlled less tightly. These findings indicate that patients with
GCA need to be indefinitely observed even after successful GC
discontinuation.
As for the time at greatest risk for relapse, in 50% of
patients who relapsed, recurrences occurred during the first
year. Mean time to first relapse was 19.718.7 months,
similar to what has been reported by others.21,23,26 However
delayed relapses also occurred.
As shown in Figure 2, PDN dose received at the time
when relapses occurred decreased over time, suggesting that
TABLE 3. Clinical Manifestations at Diagnosis in Patients With and without Relapses
Clinical characteristics Relapse (n¼68) No relapse (n¼38) p
General characteristics:
Sex, no. female/male 52/16 (76.5/23.5) 25/13 (66/34) ns
Age, mean, yr 74 6.5 76 8 ns
Cranial symptoms, n (%)
Headache 56 (82) 27 (71) ns
Jaw claudication 34 (50) 13 (34) ns
Scalp tenderness 40 (59) 9 (24) 0.001
Ischemic complications 17 (25) 9 (24) ns
Stroke 2 (3) 0 (0) ns
Transitory ischemic attack 4 (6) 0 (0) ns
Amaurosis fugax 9 (13) 6 (16) ns
Diplopia 9 (13) 2 (5) ns
Permanent visual loss 6 (9) 6 (16) ns
Polymyalgia rheumatica 40 (59) 14 (37) 0.042
Systemic manifestations, n (%)
Fever 24 (35) 16 (42) ns
Anorexia 7 (10) 5 (13) ns
Weight loss 36 (53) 18 (47) ns
Baseline laboratory parameters, meanSD
ESR, mm/hour 88 33 92 24 ns
CRP, mg/dL 11.4 18.6 10.7 15.9 ns
Haptoglobin, g/L 3.8 1.6 3.0 1.3 0.049
Hemoglobin, g/dL 11.3 1.5 11.2 1.2 ns
TABLE 4. Treatment Requirements and Side Effects During Follow-up
Clinical characteristic Relapse (n¼68) No relapse (n¼38) p
Treatment requirements
Intravenous methylprednisolone pulse* 3 (4) 4 (10.5) ns
Cumulated dose first year, meanSD (g) 6.2 1.7 5.4 0.78 0.015
Methotrexate (15mg/week) 15 (22) 1 (3) 0.009
Glucocorticoid related adverse effects n, (%)†
Diabetes mellitus 7 (10) 2 (5) ns
Systemic hypertension 37 (54) 17 (45) ns
Hypercholesterolemia 42 (62) 26 (69) ns
Osteoporosis 44 (65) 12 (32) 0.001
Cushing appearance 8 (12) 1 (3) ns
Cataracts 16 (23.5) 3 (8) ns
* At disease onset.
† 100% of patients presented at least 1 side effect.
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disease activity progressively decreases and, over the years,
lower PDN doses are required to maintain remission.
Overall, relapses occurred when patients were receiving a
mean PDN dose of 5.36.5mg/d with median 2.5mg/d
(IQR, 7.5). This dose is lower than that reported in other
series. This may be due to variability in the rate of initial
PDN tapering across different studies or to other reasons. No
patient in our cohort relapsed with PDN higher than 25mg/d.
Patients with relapses required longer periods of treatment
and were exposed to higher cumulated PDN doses, similar to
what was found in a previous study.23 All patients in our
cohort experienced at least 1 GC-related side effect. Other
studies have reported GC adverse effects in 90%-95% of GCA
patients within the first 3 years of therapy.24,26 These include
new or worsening hypertension (22%-84%),19,24,26 infections
(22%-56%),19,22,24,26 osteoporosis and bone fractures
(8%-38%),19,22–24,26 new or worsening diabetes mellitus
(7%-37%),19,22–24,26 and cataracts (4%-41%).19,24,26 The higher
frequency of side effects in our patient cohort may be related
to the longer follow-up period. We observed that patients with
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recurrences presented more GC-related toxicity, in particular
osteoporosis despite the administration of calcium supple-
ments, vitamin D, and bisphosphonates. These data highlight
the need for more efficient and safer therapies.
In the current cohort, relapses could not be attributed to
insufficient treatment because relapsing patients received
more GC and for more extended periods of time. This
observation indicates that some patients have a more resistant
disease. From the clinical standpoint, an intense acute-phase
response was associated with higher risk of relapse. Other
investigators have also observed that abnormalities related to
the acute-phase response are predictors of
relapse.6,9,12,14,23,25,28 Among other findings, only scalp ten-
derness and PMR were slightly more frequent in relapsing
patients. Although this association may be spurious, a similar
trend has been observed in other studies.23 Previous studies
have investigated tissue and serum biomarkers associated with
persistent disease activity and relapsing course. Elevated
serum concentrations of tumor necrosis factor (TNF)-α,
interleukin (IL)-6, and soluble intercellular adhesion molecule
(ICAM)-1 are associated with relapsing disease.10,12,28 In-
creased expression of TNF-α or chemokine (C-C motif) ligand
(CCL)-2 mRNA in involved arteries is associated with
recurrent disease and higher GC requirements. However, TNF-
α blockade was not sufficient to reduce relapses and spare
corticosteroids,16 indicating that association does not imply
causality and suggesting that TNF-α effects may be compen-
sated by other cytokines and that upstream mediators may be
more relevant to perpetuate disease activity. Elevated mRNA
concentrations of Th1 cytokines IL-12/23p40 and interferon
(IFN)-γ have been observed after 1 year of treatment in second
temporal artery biopsies of relapsing patients, suggesting re-
activation of initial events able to drive subsequent inflamma-
tory cascades.28 In contrast, increased IL-17 expression in
GCA lesions is a predictor of sustained response to GC.11
Further research is needed to elucidate the mechanisms
involved in disease persistence, to enable the design of more
specific and efficient targeted therapies.
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